Elan boosted after positive drug news

SHARES in Elan rose yesterday following the release of positive data from trials of its multiple sclerosis treatment Tysabri.

Two reviews of the drug published in The New England Journal of Medicine have highlighted no new safety concerns.

Tysabri was withdrawn from sale a year ago after some patients taking the treatment in conjunction with another drug, Avonex, developed a fatal brain disease.